FNArena Windows
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
| ASX CODE | LAST PRICE | % MOVE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET | UPSIDE/DOWNSIDE |
|---|---|---|---|---|---|---|---|
| 4DX | $3.71 |
|
$7.55 | $0.23 | -20.7 |
$4.50 |
|
| AT1 | $0.02 | 0.00% | $0.05 | $0.01 |
|
||
| BB1 | $0.64 |
|
$1.11 | $0.41 |
$1.76 |
|
|
| BRN | $0.17 |
|
$0.27 | $0.13 |
|
||
| CAT | $3.16 |
|
$7.72 | $2.86 |
$5.134 |
|
|
| CBL | $0.09 | 0.00% | $0.10 | $0.03 |
|
||
| CGS | $2.73 |
|
$2.97 | $1.35 | 29.8 |
$3.20 |
|
| CMP | $0.27 |
|
$0.45 | $0.24 |
|
||
| COH | $111.32 |
|
$319.56 | $88.74 | 23.6 |
$116.028 |
|
| CSX | $0.40 | 0.00% | $0.88 | $0.32 |
|
||
| CTE | $1.06 | 0.00% | $1.30 | $0.66 |
|
||
| CU6 | $2.21 |
|
$5.87 | $1.97 |
$6.50 |
|
|
| CVB | $0.04 | 0.00% | $0.18 | $0.04 |
|
||
| EBR | $0.38 | 0.00% | $1.48 | $0.37 |
$2.235 |
|
|
| EIQ | $1.22 |
|
$1.46 | $0.17 |
$1.40 |
|
|
| EMV | $1.54 | 0.00% | $2.43 | $1.48 |
$3.15 |
|
|
| EYE | $0.12 | 0.00% | $0.21 | $0.10 |
|
||
| FPH | $32.01 |
|
$35.31 | $26.51 | 40.6 |
|
|
| IME | $0.35 |
|
$0.47 | $0.22 | 16.7 |
$0.50 |
|
| IMR | $1.89 |
|
$2.25 | $1.15 |
$2.61 |
|
|
| IPD | $0.01 | 0.00% | $0.06 | $0.01 |
$0.018 |
|
|
| LDX | $0.11 |
|
$0.33 | $0.03 |
|
||
| MX1 | $0.04 | 0.00% | $0.12 | $0.04 |
$0.15 |
|
|
| NAN | $3.19 |
|
$4.77 | $2.96 | 57.0 |
$3.80 |
|
| ONE | $0.17 | 0.00% | $0.41 | $0.16 |
$0.45 |
|
|
| PCK | $0.12 | 0.00% | $0.35 | $0.03 |
|
||
| PEB | $0.25 |
|
$0.26 | $0.08 |
|
||
| PGC | $0.14 | 0.00% | $0.41 | $0.14 | 10.8 |
$0.25 |
|
| PME | $168.90 |
|
$336.00 | $107.75 | 90.6 |
$218.667 |
|
| RAP | $0.05 | 0.00% | $0.07 | $0.03 |
|
||
| RMD | $27.55 |
|
$45.25 | $25.50 | 16.5 |
$41.143 |
|
| SHG | $0.20 | 0.00% | $0.42 | $0.19 |
|
||
| SOM | $0.55 |
|
$0.95 | $0.50 | 34.4 |
$0.99 |
|
| TRJ | $0.25 |
|
$0.97 | $0.25 | 13.5 |
$0.825 |
|
-0.27% 
21.3% Previous Stories
Fisher & Paykel Healthcare: Lower Margin, Higher Spending
May 30 2023
Following FY23 results for Fisher & Paykel, brokers lowered earnings forecasts on a delayed margin recovery and future spending plans
Dr Boreham’s Crucible: Impedimed
May 08 2023
Tim Boreham reports a change in CEO has given cancer monitoring biotech Impedimed a new lease of life
Treasure Chest: ResMed’s Benevolent Monopoly
May 01 2023
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is ResMed
Dr Boreham’s Crucible: Volpara Health Technologies
Apr 26 2023
Volpara Health Technologies is revolutionising breast cancer detection. Tim Boreham investigates
Dr Boreham’s Crucible: SDI
Mar 16 2023
Tim Boreham gets his teeth into the opportunity ahead for listed dental products company SDI
Dr Boreham’s Crucible: Cochlear
Mar 03 2023
Short term hiccups aside, Cochlear continues to play the long game, reports Tim Boreham
Dr Boreham’s Crucible: Imagion Biosystems
Feb 13 2023
Tim Boreham reports Imagion’s CEO believes the oncology imaging innovator has achieved far more with its initial early-stage breast cancer study results than investors might appreciate.
ResMed: Philips Remains The Big Unknown
Jan 31 2023
Lack of competition, alongside improved component supply, sees ResMed deliver a strong second quarter